ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of 18,602,941 shares of its common stock,
November 30, 2018
· 2 min read